BRISTOL MYERS SQUIBB

Bristol Myers Squibb's Sotyktu, a TYK2 inhibitor, showed positive Phase 3 results in psoriatic arthritis, potentially expanding its use beyond plaque psoriasis. The drug met primary and secondary goals in two studies, offering a safer alternative to JAK inhibitors. BMS aims to discuss these results with health authorities to fend off competition from other TYK2 inhibitors.

2024 saw significant medical breakthroughs, including gene therapy restoring hearing in children, the first genetically-edited pig kidney transplant into a human, discovery of a lupus cause, FDA approval of the first new schizophrenia drug class in over 30 years, and the first over-the-counter COVID-19 and flu test outside of emergency use.

The European Commission approved Opdivo plus Yervoy for first-line treatment of MSI-H/dMMR mCRC, based on CheckMate -8HW trial results showing significant PFS improvement and reduced risk of disease progression or death compared to chemotherapy.

Bristol Myers Squibb announced positive Phase III results for Sotyktu in psoriatic arthritis, showing greater treatment response vs. placebo. Sotyktu, an oral TYK2 inhibitor, is FDA-approved for plaque psoriasis and saw $170m in sales in 2023, projected to rise to $2.2bn by 2030.

Dermatology Times reflects on progress in skin health equity, addressing disparities in care for skin of color, women, LGBTQ+ patients, and underserved populations, highlighting advocacy and challenges shaping a more inclusive future in dermatology in 2024.

The 'Beta Thalassaemia - Global Clinical Trials Review, 2024' report by ResearchAndMarkets.com offers an overview of clinical trials, including trial numbers, enrollment, regions, countries, phases, status, and sponsor types. It highlights prominent drugs and companies involved, aiding decision-making and identifying opportunities in the global clinical trials market.

Bristol Myers Squibb's late-stage studies of plaque psoriasis drug Sotyktu met key goals in psoriatic arthritis, achieving significant improvement in symptoms after 16 weeks. The FDA approved Sotyktu in 2022 for moderate-to-severe plaque psoriasis, with $163 million in sales for the first nine months of 2024.

Bristol Myers Squibb announced successful Phase 3 trials of Sotyktu in treating active psoriatic arthritis, with significantly higher patient improvement compared to placebo. The drug, already approved for moderate-to-severe plaque psoriasis, could be the first TYK2 inhibitor for PsA patients. The company plans to present trial data at medical congresses and engage with health authorities.

Bristol Myers Squibb announces European Commission approval of Opdivo and Yervoy as first-line treatment for MSI-H/dMMR metastatic colorectal cancer, based on Phase 3 CheckMate -8HW trial results showing 79% reduction in disease progression or death risk compared to chemotherapy. The approval extends across all 27 EU member states, Iceland, Liechtenstein, and Norway.